secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001564590-23-002126
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera FY2022 revenue $485M, net income $158.5M; 23 new partnered programs started
--------------------------------------------------------------------------------

- Total revenue $485.4M (up 29% YoY); net income $158.5M ($0.50 diluted EPS) vs $153.5M ($0.48 diluted) in 2021.
- Royalties from COVID antibodies bamlanivimab/bebtelovimab were $443M; EUA for bebtelovimab suspended in Q4.
- Partnership business: 23 new program starts, cumulative 101; 174 programs under contract with 40 partners.
- Q4 net loss $29.9M; cash and marketable securities $886.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/0001564590-23-002126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459023002126/abcl-8k_20230221.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-002126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer